Virtual reality for cancer pain relief and opioid reduction
Official title: Digital Intervention for Symptom Management in Cancer and Opioid Sparing Using Virtual Reality (DISCOVR) - Feasibility, Acceptability, Usability Testing of a Novel Intervention
Run by Medstar Health Research Institute · NCT07228377 · Data updated 2026-11-12
This project will try virtual reality headsets with adults who have chronic moderate-to-severe cancer pain and take opioids to see if it lowers pain and opioid needs.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 25 (estimated) |
| Sponsor | Medstar Health Research Institute Academic / other |
| Locations | 1 site (Washington D.C., District of Columbia) |
| Status | Recruiting |
| Started | December 1, 2025 |
| Main results expected | August 31, 2026 |
| Study ends | August 31, 2026 |
| Registry record updated | December 24, 2025 |
| Trial ID | NCT07228377 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with an active solid-tumor cancer diagnosis, chronic cancer-related pain lasting at least three months with baseline pain ≥4/10, and who are prescribed chronic opioid therapy are ideal candidates.
✕Probably not a fit
Patients whose pain is primarily non-cancer in origin, or who have contraindications to VR such as seizure disorder, severe motion sickness, cranial abnormalities preventing headset use, or inability to complete surveys in English or Spanish are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Investigators will gather patient input and stakeholder feedback to design a VR program tailored to chronic cancer pain and build a patient-centered prototype. They will enroll adults with active solid tumors who report chronic cancer pain (≥3 months) with baseline pain ≥4/10 and who are prescribed chronic opioid therapy to test feasibility, acceptability, usability, and safety. The work uses an iterative development process with interviews, prototype testing, patient-reported outcomes, and safety monitoring, refining the VR intervention based on participant feedback. Successful completion will inform larger trials examining efficacy and opioid-sparing effects.
Why it matters
Potential benefit: If successful, a patient-centered VR program could reduce cancer-related pain, improve quality of life, and lower reliance on opioid medications.
How similar studies have gone: Previous VR research has shown promising pain relief in acute and some chronic pain conditions, but VR has not been extensively tested specifically for chronic cancer pain, so evidence is encouraging but limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age ≥18 years old * living with active cancer diagnosis (any solid tumor type) * report chronic cancer pain (≥3 months) with baseline severity moderate-severe (i.e., self-report pain score (SRPS) ≥4/10, where 0=no pain, 10=worst pain) * prescribed chronic opioid therapies (may be long-acting formulations, short-acting formulations, or both) Exclusion Criteria: * history of intractable nausea/vomiting, motion sickness, seizures/epilepsy, and/or cranial structure abnormalities preventing VR headset use * moderate-severe pain of non-cancer etiology (e.g., chronic lumbago) * enrolled in another pain study * unable to complete surveys in English or Spanish.
Where it's running
-
MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center
Washington D.C., District of Columbia, United States Recruiting
Study contacts
- Principal investigator: Hunter Groninger, MD — Medstar Health Research Institute
- Study coordinator: Hunter Groninger, MD
- Email: hunter.groninger@medstar.net
- Phone: 202-877-7445
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.